A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.